These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Bortezomib-induced histiocytoid Sweet syndrome.
    Author: Murase JE, Wu JJ, Theate I, Cole GW, Barr RJ, Dyson SW.
    Journal: J Am Acad Dermatol; 2009 Mar; 60(3):496-7. PubMed ID: 19231647.
    Abstract:
    Bortezomib, a proteasome inhibitor approved for the treatment of multiple myeloma, has been reported to be associated with Sweet syndrome. However, careful review of the histopathology of the first reported case and our case revealed similar histologic and immunohistochemical findings (a mononuclear dermal infiltrate) and not the usual neutrophilic infiltrate of Sweet syndrome. We suggest that the dermatitis induced by bortezomib is best classified as "histiocytoid Sweet syndrome."
    [Abstract] [Full Text] [Related] [New Search]